BGG492
BGG492 is a pharmaceutical drug with 7 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 4 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
7
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
57.1%
4 of 7 finished
42.9%
3 ended early
0
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Phase II BGG492 Capsule Extension for Partial Epilepsy
Efficacy and Safety of BGG492 in the Treatment of Migraine
Efficacy of 5 Weeks of Treatment With BGG492 in Patients With Spasticity Due to Multiple Sclerosis
A Randomized,Double Blind, Placebo Controlled Study to Assess Efficacy,Safety and Tolerability of BGG492 in Migraine Prevention
Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492
Clinical Trials (7)
Phase II BGG492 Capsule Extension for Partial Epilepsy
Efficacy and Safety of BGG492 in the Treatment of Migraine
Efficacy of 5 Weeks of Treatment With BGG492 in Patients With Spasticity Due to Multiple Sclerosis
A Randomized,Double Blind, Placebo Controlled Study to Assess Efficacy,Safety and Tolerability of BGG492 in Migraine Prevention
Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492
Effect of BGG492 on EEG in Patients With Photosensitive Epilepsy
Evaluate the Efficacy of BGG492 as Adjunctive Treatment in Patients With Refractory Partial Onset Seizures
All 7 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 7